Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 16, 2024 (the "Effective Date"), Mark Austin, the Vice President of Finance, Corporate Controller and Corporate Secretary of Perspective Therapeutics, Inc. (the "Company"), ceased serving as an executive officer and as the Company's "co-principal financial officer" and "principal accounting officer." Effective as of the Effective Date, Jonathan Hunt, the Company's Chief Financial Officer and "co-principal financial officer," began serving as the Company's sole "principal financial officer" and "principal accounting officer."

Full biographical information and business experience for Mr. Hunt, age 57, are described in the Company's proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 18, 2024. There are no arrangements or understandings between Mr. Hunt and any other persons pursuant to which Mr. Hunt was designated as the "principal financial officer" or "principal accounting officer" of the Company. There are also no family relationships between Mr. Hunt and any director or executive officer of the Company, and Mr. Hunt has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.